During the past decade, Universitätsklinikum Erlangen; Frauenklinik conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 10 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 6 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitätsklinikum Erlangen; Frauenklinik" #1 sponsor was "Hoffmann-La Roche" with 13 trials, followed by "University Hospital Tuebingen" with 3 trials sponsored, "Ethicon, Inc." with 1 trials sponsored, "Galena Biopharma, Inc." with 1 trials sponsored and "Pfizer" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinikum Erlangen; Frauenklinik" #1 collaborator was "Breast International Group" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "German Breast Group" with 1 trials as a collaborator, "Gilead Sciences" with 1 trials as a collaborator and "NSABP Foundation Inc" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsklinikum Erlangen; Frauenklinik" are "Breast Cancer" (5 trials), "Breast Neoplasms" (3 trials), "Early Breast Cancer" (2 trials), "Metastatic Breast Cancer" (2 trials) and "Triple Negative Breast Cancer" (2 trials). Many other conditions were trialed in "Universitätsklinikum Erlangen; Frauenklinik" in a lesser frequency.

Most popular intervention types in "Universitätsklinikum Erlangen; Frauenklinik" are "Drug" (14 trials), "Procedure" (2 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Trastuzumab" (4 trials), "Docetaxel" (3 trials), "Pertuzumab" (3 trials) and "Trastuzumab Emtansine" (3 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinikum Erlangen; Frauenklinik" are 12 trials for "All" genders and 8 trials for "Female" genders.

Currently, there are NaN active trials in "Universitätsklinikum Erlangen; Frauenklinik". undefined are not yet recruiting, 3 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Universitätsklinikum Erlangen; Frauenklinik, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinikum Erlangen; Frauenklinik, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".